Axsome Net Income From Continuing Ops from 2010 to 2026
| AXSM Stock | USD 186.18 1.44 0.78% |
Net Loss | First Reported 2013-12-31 | Previous Quarter -48 M | Current Value -47.2 M | Quarterly Volatility 25.4 M |
Check Axsome Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Axsome Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 9.6 M, Interest Expense of 7.9 M or Selling General Administrative of 374.5 M, as well as many indicators such as Price To Sales Ratio of 11.48, Dividend Yield of 0.0 or PTB Ratio of 67.19. Axsome financial statements analysis is a perfect complement when working with Axsome Therapeutics Valuation or Volatility modules.
Axsome | Net Income From Continuing Ops | Build AI portfolio with Axsome Stock |
Evaluating Axsome Therapeutics's Net Income From Continuing Ops across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Axsome Therapeutics's fundamental strength.
Latest Axsome Therapeutics' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Axsome Therapeutics over the last few years. It is Axsome Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Axsome Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Axsome Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (96,981,058) | |
| Coefficient Of Variation | (108.49) | |
| Mean Deviation | 90,840,176 | |
| Median | (30,965,464) | |
| Standard Deviation | 105,214,469 | |
| Sample Variance | 11070.1T | |
| Range | 281.2M | |
| R-Value | (0.92) | |
| Mean Square Error | 1847.8T | |
| R-Squared | 0.84 | |
| Slope | (19,136,044) | |
| Total Sum of Squares | 177121.4T |
Axsome Net Income From Continuing Ops History
About Axsome Therapeutics Financial Statements
Axsome Therapeutics investors utilize fundamental indicators, such as Net Income From Continuing Ops, to predict how Axsome Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -258.5 M | -245.6 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Axsome Therapeutics Correlation against competitors. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Will Pharmaceuticals sector continue expanding? Could Axsome diversify its offerings? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Axsome Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (4.67) | Revenue Per Share | Quarterly Revenue Growth 0.632 | Return On Assets | Return On Equity |
Investors evaluate Axsome Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Axsome Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Axsome Therapeutics' market price to deviate significantly from intrinsic value.
Understanding that Axsome Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Axsome Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Axsome Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.